. Saint-jean-hospital, :. H. Perpignan, F. Aumaître, M. Borsato, M. Malet et al., Saint-Germain en Laye Hospital, N. Bentaleb, A. Blondin-Diop

S. Molina, J. Parlier, C. Pavie, D. Pintado, A. Ponscarme et al., Saint André Hospital, Hô tel Dieu Hospital

M. Pennel, N. Valette, Y. Viget, . Yazdanpanah, . De-brabois-hospital et al., Nord Hospital, Cré teil Hospital

O. Events-review-committee, G. Lortholary, E. Breton, T. Caumes, C. May et al., The study team also included C. Gué rin, protocol pharmacist, F. Altare, A. Bourgarit and G. Carcelain in charge of the BKVIRIS substudy, Lisa Chakrabarti in charge of the BKVIR Cytok substudy, Clinical Trials Unit/INSERM, vol.897

L. Aaron, D. Saadoun, and I. Calatroni, Tuberculosis in HIV-infected patients: a comprehensive review, Clin Microbiol Infect, vol.10, pp.388-98, 2004.

J. Del-amo, S. Moreno, and H. C. Bucher, Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries, Clin Infect Dis, vol.54, pp.1364-72, 2012.

, Guidelines Version 6.0. Octobre, European AIDS Clinical Society, 2011.

, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington: Department of Health and Human Services, 2013.

F. Lanternier, C. Dalban, and L. Perez, Tolerability of anti-tuberculosis treatment and HIV serostatus, Int J Tuberc Lung Dis, vol.11, pp.1203-1212, 2007.

W. Manosuthi, S. Sungkanuparph, and P. Tantanathip, A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study, Clin Infect Dis, vol.48, pp.1752-1761, 2009.

L. J. Haddow, M. Y. Moosa, and P. J. Easterbrook, Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome, AIDS, vol.24, pp.103-111, 2010.

G. Meintjes, S. D. Lawn, and F. Scano, Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings, Lancet Infect Dis, vol.8, pp.516-539, 2008.

P. C. Onyebujoh, I. Ribeiro, and C. C. Whalen, Treatment options for HIV-associated tuberculosis, J Infect Dis, issue.1, pp.35-45, 0196.

J. B. Nachega, J. J. Parienti, and O. A. Uthman, Lower pill burden and oncedaily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials, Clin Infect Dis, vol.58, pp.1297-307, 2014.

C. Rouzioux, A. Melard, and V. Avettand-fenoel, Quantification of total HIV1-DNA in peripheral blood mononuclear cells, Methods Mol Biol, vol.1087, pp.261-70, 2014.

M. Boffito, J. Tija, and H. E. Reynolds, Simultaneous determination of rifampicin and efavirenz in plasma, Ther Drug Monit, vol.24, pp.670-674, 2002.

C. A. Peloquin, G. S. Jaresko, and C. L. Yong, Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide, Antimicrob Agents Chemother, vol.41, pp.2670-2679, 1997.

A. Alsultan and C. A. Peloquin, Therapeutic drug monitoring in the treatment of tuberculosis: an update, Drugs, vol.74, pp.839-54, 2014.

M. A. French, P. Price, and S. F. Stone, Immune restoration disease after antiretroviral therapy, AIDS, vol.18, pp.1615-1642, 2004.

W. Manosuthi, H. Van-tieu, and W. Mankatitham, Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome, AIDS, vol.23, pp.2467-71, 2009.

A. L. Pozniak, K. M. Coyne, and R. F. Miller, British HIV Association guidelines for the treatment of TB/HIV coinfection 2011, HIV Med, vol.12, pp.517-541, 2011.

C. Jack, U. Lalloo, and Q. A. Karim, A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting, J Acquir Immune Defic Syndr, vol.36, pp.929-963, 2004.

A. Patel, K. Patel, and J. Patel, Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1

, J Acquir Immune Defic Syndr, vol.37, pp.1166-1175, 2004.

W. Manosuthi, S. Sungkanuparph, and A. Thakkinstian, Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin, AIDS, vol.19, pp.1481-1487, 2005.

W. Manosuthi, S. Kiertiburanakul, and S. Sungkanuparph, Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results, AIDS, vol.20, pp.131-133, 2006.

A. Boulle, G. Van-cutsem, and K. Cohen, Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy, JAMA, vol.300, pp.530-539, 2008.

L. K. Shipton, C. W. Wester, and S. Stock, Safety and efficacy of nevirapineand efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana, Int J Tuberc Lung Dis, vol.13, pp.360-366, 2009.

L. F. Lopez-cortes, R. Ruiz-valderas, and P. Viciana, Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis, Clin Pharmacokinet, vol.41, pp.681-90, 2002.

P. Brennan-benson, R. Lyus, and T. Harrison, Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all, AIDS, vol.19, pp.1541-1544, 2005.

W. Stohr, D. Back, and D. Dunn, Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity

, Antivir Ther, vol.13, pp.675-85, 2008.

G. Friedland, S. Khoo, and C. Jack, Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV, J Antimicrob Chemother, vol.58, pp.1299-302, 2006.

C. Orrell, K. Cohen, and F. Conradie, Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?, Antivir Ther, vol.16, pp.527-561, 2011.

W. Manosuthi, S. Sungkanuparph, and P. Tantanathip, Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin, Antimicrob Agents Chemother, vol.53, pp.4545-4553, 2009.

J. Villar, P. Sanchez, and A. Gonzalez, Use of non-nucleoside analogues together with rifampin in HIV patients with tuberculosis, HIV Clin Trials, vol.12, pp.171-175, 2011.

A. F. Luetkemeyer, S. L. Rosenkranz, and D. Lu, Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study, Clin Infect Dis, vol.57, pp.586-93, 2013.

M. Bonnet, N. Bhatt, and E. Baudin, Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised noninferiority trial, Lancet Infect Dis, vol.13, pp.303-315, 2013.

H. Mcilleron, R. Rustomjee, and M. Vahedi, Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines, Antimicrob Agents Chemother, vol.56, pp.3232-3240, 2012.

D. C. Perlman, Y. Segal, and S. Rosenkranz, The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis, Clin Infect Dis, vol.41, pp.1638-1685, 2005.

F. Fahimi, P. Tabarsi, and F. Kobarfard, Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis, Int J Tuberc Lung Dis, vol.17, pp.1602-1608, 2013.

N. B. Bhatt, C. Barau, and A. Amin, Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment, Antimicrob Agents Chemother, vol.58, pp.3182-90, 2014.

A. Kwara, L. Cao, and H. Yang, Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance, Pharmacotherapy, vol.34, pp.265-71, 2014.

J. E. Conte, J. A. Golden, and J. E. Kipps, Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin, Clin Pharmacokinet, vol.43, pp.395-404, 2004.

J. J. Wilkins, G. Langdon, and H. Mcilleron, Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients, Br J Clin Pharmacol, vol.72, pp.51-62, 2011.

D. P. Holland, C. D. Hamilton, and A. C. Weintrob, Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection, Pharmacotherapy, vol.29, pp.503-513, 2009.

S. Chideya, C. A. Winston, and C. A. Peloquin, Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana, Clin Infect Dis, vol.48, pp.1685-94, 2009.

E. Burhan, C. Ruesen, and R. Ruslami, Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients, Antimicrob Agents Chemother, vol.57, pp.3614-3623, 2013.

J. G. Pasipanodya, H. Mcilleron, and A. Burger, Serum drug concentrations predictive of pulmonary tuberculosis outcomes, J Infect Dis, vol.208, pp.1464-73, 2013.

C. J. Hoffmann, S. Charalambous, and C. L. Thio, Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B, AIDS, vol.21, pp.1301-1309, 2007.

A. Karim, S. S. Naidoo, K. Grobler, and A. , Integration of antiretroviral therapy with tuberculosis treatment, N Engl J Med, vol.365, pp.1492-501, 2011.

F. X. Blanc, T. Sok, and D. Laureillard, Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis, N Engl J Med, vol.365, pp.1471-81, 2011.

B. Grinsztejn, D. Castro, N. , and A. V. , Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial, Lancet Infect Dis, vol.14, pp.459-67, 2014.

. Lortholary,

Y. C. Manabe, R. Breen, and T. Perti, Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy, J Infect Dis, vol.199, pp.437-481, 2009.

R. Colebunders, L. John, and V. Huyst, Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources, Int J Tuberc Lung Dis, vol.10, pp.946-53, 2006.

C. Michailidis, A. L. Pozniak, and S. Mandalia, Clinical characteristics of IRIS syndrome in patients with HIVand tuberculosis, Antivir Ther, vol.10, pp.417-439, 2005.

S. D. Lawn, L. Myer, and L. G. Bekker, Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa, AIDS, vol.21, pp.335-376, 2007.

L. J. Haddow, P. J. Easterbrook, and A. Mosam, Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort, Clin Infect Dis, vol.49, pp.1424-1456, 2009.

D. Laureillard, O. Marcy, and Y. Madec, Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial, AIDS, vol.27, pp.2577-86, 2013.

M. Muller, S. Wandel, and R. Colebunders, Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis, Lancet Infect Dis, vol.10, pp.251-61, 2010.

D. V. Havlir, M. A. Kendall, and P. Ive, Timing of antiretroviral therapy for HIV-1 infection and tuberculosis, N Engl J Med, vol.365, pp.1482-91, 2011.

L. A. Chakrabarti, C. Boucherie, and F. Bugault, Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome, AIDS, vol.28, pp.1593-602, 2014.
URL : https://hal.archives-ouvertes.fr/pasteur-01092056

A. F. Luetkemeyer, M. A. Kendall, and M. Nyirenda, Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs, J Acquir Immune Defic Syndr, vol.65, pp.423-431, 2014.

K. Naidoo, N. Yende-zuma, and N. Padayatchi, The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial, Ann Intern Med, vol.157, pp.313-337, 2012.